October 28, 2016
Astellas Pharma is to acquire Ganymed Pharmaceuticals AG (Mainz, Germany) in a bid to build upon its oncology franchise as a platform for sustainable growth. Astellas will pay €422 million ($460m) to acquire 100% of the equity in Ganymed. In addition, Ganymed's shareholders will become eligible to receive up to €860 million ($938m) in further contingent payments based on progress in the development of IMAB362, Ganymed's most advanced clinical program. Upon completion of the transaction, Ganymed would become a wholly owned subsidiary of Astellas. The closing of the transaction is subject to customary regulatory approvals and is expected to be finalized in the next several weeks. Ganymed is a privately-held biopharma company founded in 2001 and focusing on the development of a new class of cancer drugs. It has several oncology pipeline assets in pre-clinical and clinical stages.
Can Data and AI Deliver Whole-Person Health?
July 9th 2024Executives in the life sciences and medical device industries see promise in artificial intelligence (AI) and medical technologies, but must also navigate the changing healthcare ecosystem, varied stakeholder needs, and the impact of AI on market access and commercialization strategies.